Clinical Trial Update: A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency [Phase 2]

View source ↗

Summary

Phase 2 trial update of AEB1102 (pegzilarginase) in patients with Arginase I deficiency completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arginase Deficiency
• Hyperargininemia

Drugs mentioned

• AEB1102

Snippet

Sponsor: Aeglea Biotherapeutics | Conditions: Arginase I Deficiency, Hyperargininemia | Phase 2 | Status: COMPLETED